Literature DB >> 29928779

QT correction across the heart rate spectrum, in atrial fibrillation and ventricular conduction defects.

Bert Vandenberk1,2, Eline Vandael3, Tomas Robyns1,2, Joris Vandenberghe4, Christophe Garweg1,2, Veerle Foulon3, Joris Ector1,2, Rik Willems1,2.   

Abstract

BACKGROUND: Incorporation of QTc in clinical decision support systems requires accurate QT-interval correction, also during common electrocardiogram abnormalities as ventricular conduction defects (VCD). We compared the performance and predictive value of QT correction formulas to design a patient-specific QT correction algorithm (QTcA).
METHODS: The first ECG in adult patients with sinus rhythm (SR), atrial fibrillation (AF), and ventricular pacing (VP) was collected retrospectively. QT correction was performed with Bazett (QTcB), Fridericia (QTcFri), Framingham, Hodges, and Rautaharju (QTcR) formulas. Correction formulas were compared using QTc/RR linear regression. Adjusted Cox regression was performed to predict 1-year all-cause mortality.
RESULTS: A total of 49,737 patients were included (70.0% SR, 24.1% AF, 5.9% VP, 11.1% VCD). Overall 1-year all-cause mortality rate was 11.8%. In patients without VCD or VP, QTcFri showed significantly better heart rate correction, both overall (P < 0.001) and in subgroups by heart rate (bradycardia P ≤ 0.001, normal P ≤ 0.050, tachycardia P ≤ 0.010). Furthermore, QTcFri improved mortality prediction significantly when compared to QTcB (P < 0.001). Patients with VCD or VP QTcR, including correction for QRS duration, had a significant better heart rate correction than QTcB (P ≤ 0.010) and improved mortality prediction significantly compared to all other formulas (P < 0.001). Implementing QTcA, designed based on QTcFri and QTcR depending on the presence of VCD or VP, reduced the patients considered to be at risk by 61.1% when compared to QTcB.
CONCLUSIONS: A patient-specific QT correction algorithm would combine accurate heart rate correction, improved predictive value of mortality, and a reduction of patients considered to be at risk.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  QT-interval; electrocardiography; mortality; population; risk stratification

Mesh:

Year:  2018        PMID: 29928779     DOI: 10.1111/pace.13423

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  6 in total

1.  Estimation of cardiac QTc intervals in people prescribed antipsychotics: a comparison of correction factors.

Authors:  Teodora Andric; Karl Winckel; Timothy David Tanzer; Samantha Hollingworth; Lesley Smith; Katherine Isoardi; Olivier Tan; Dan Siskind
Journal:  Ther Adv Psychopharmacol       Date:  2022-06-16

2.  Heart-Rate-Corrected QT Interval Response to Ramosetron during Robot-Assisted Laparoscopic Prostatectomy: A Randomized Trial.

Authors:  Bora Lee; So Yeon Kim; Seung Hyun Kim; Hyukjin Yang; Jeong Hyun Jin; Seung Ho Choi
Journal:  J Pers Med       Date:  2022-05-18

3.  Declining Levels and Bioavailability of IGF-I in Cardiovascular Aging Associate With QT Prolongation-Results From the 1946 British Birth Cohort.

Authors:  Christos Charalambous; James C Moon; Jeff M P Holly; Nishi Chaturvedi; Alun D Hughes; Gabriella Captur
Journal:  Front Cardiovasc Med       Date:  2022-04-22

Review 4.  Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients.

Authors:  Megan E Klatt; Gregory A Eschenauer
Journal:  J Fungi (Basel)       Date:  2021-01-22

5.  Repolarization abnormalities on admission predict 1-year outcome in COVID-19 patients.

Authors:  Bert Vandenberk; Matthias M Engelen; Greet Van De Sijpe; Jonas Vermeulen; Stefan Janssens; Thomas Vanassche; Peter Verhamme; Paul De Munter; Natalie Lorent; Rik Willems
Journal:  Int J Cardiol Heart Vasc       Date:  2021-11-03

6.  The QT Interval Dynamic in a Human Experimental Model of Controlled Heart Rate and QRS Widening.

Authors:  Santiago Colunga; Remigio Padrón; Daniel García-Iglesias; José Manuel Rubín; Diego Pérez; Raquel Del Valle; Pablo Avanzas; César Morís; David Calvo
Journal:  J Clin Med       Date:  2019-09-09       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.